Fused Bicyclic Pyridine Compounds for Selective AMPA Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AMPA receptor antagonists have narrow therapeutic dosing windows, leading to undesired effects such as ataxia, sedation, and dizziness due to non-selective modulation of AMPA receptors across the central nervous system, and they are ineffective for treating conditions like epilepsy and neurotoxicity, which require selective modulation of AMPA receptor activity.
Innovation Solution
Development of compounds that selectively modulate TARP γ8-associated AMPA receptors, reducing side effects by targeting specific AMPA receptor complexes in the hippocampus and cortex, thereby providing therapeutic benefits for conditions like epilepsy, schizophrenia, and mood disorders without the broad CNS effects of non-selective antagonists.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If general AMPA receptor antagonists are used to treat CNS disorders, then anticonvulsant activity is achieved, but undesired effects such as ataxia, sedation, and dizziness occur due to non-selective modulation
Solution Approach 1:
The patent applies local quality by designing compounds that selectively modulate AMPA receptors in specific brain regions (hippocampus and cortex) rather than uniformly affecting all AMPA receptors throughout the CNS. This regional selectivity achieves anticonvulsant activity while minimizingundesired effects like ataxia and sedation that result from broad CNS suppression.
Solution Approach 2:
The invention segments the AMPA receptor modulation function by creating compounds with differential affinity for various AMPA receptor subtypes and configurations. This segmentation allows selective targeting of pathological circuits involved in seizures while sparing normal physiological functions, thereby resolving the contradiction between therapeutic efficacy and side effect profile.
2Reliability
If AMPA receptor activity is broadly inhibited to treat epilepsy, then seizure control is achieved, but therapeutic dosing window becomes narrow and side effects increase
Solution Approach 1:
The compounds exhibit local quality by demonstrating region-specific and subtype-selective AMPA receptor modulation. This selectivity creates a wider therapeutic dosing window because effective seizure control can be achieved at doses that do not excessively suppress AMPA receptor activity in healthy brain regions, thereby reducing side effects and improving ease of dosing.
3Adaptability or versatility
If non-selective AMPA receptor antagonists are used, then broad CNS effects are achieved, but selective modulation of specific AMPA receptor complexes is lost
Solution Approach 1:
The patent implements local quality by engineering compounds with specific molecular features that confer selectivity for particular AMPA receptor complexes (such as those containing TARP γ8). This enables precise modulation of target receptors while maintaining the ability to achieve broad therapeutic effects across multiple indications through selective action on pathologically relevant receptor populations.
Data Source
AI summary
Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, (I) Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).